Kidney Cancer Drugs Market - Top Companies and Manufacturers

Companies Dominating the Kidney Cancer Drugs Landscape:

The kidney cancer drugs market is competitive owing to the strong presence of established companies and the emergence of start-ups. The key players are investing heavily in the production of advanced kidney cancer drugs market. This move is set to increase their market reach and earn high profits. Industry giants are also adopting marketing tactics such as collaboration with research institutions to develop innovative kidney cancer drugs and partnerships with other players to boost their regional expansion. New companies are focused on the development of cutting-edge kidney cancer diagnostic and therapeutic solutions to stand out in the crowd.

AbbVie
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Arlak Biotech
Apikos Pharma
Astellas Pharma
AstraZeneca Plc
Amgen Inc.
Biogen Inc.
Baxter International Inc.
Byer AG
GlaxoSmithKline Plc
JW Therapeutics
Johnson & Johnson
Merck & Co., Inc.
Novo Nordisk A/S

Browse Key Market Insights with Data Illustration:

Kidney Cancer Drugs Market Size & Share, Growth Forecasts 2037

In the News

In June 2024, Scientists from the Wistar Institute developed a novel antibody treatment for kidney cancer. The advanced recombinant and synthetic DNA versions of therapeutic antibodies are showing long-lasting and promising results against clear cell renal cell carcinoma (ccRCC).
In December 2023, The U.S. Food and Drug Administration approved the use of belzutifan for metastatic kidney cancer treatment. Belzutifan developed by the UT Southwestern Researchers was first approved by the FDA in 2021 and in 2023 it received approval for its expanded use.
In December 2023, Merck received FDA approval for the use of WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. WELIREG is used for the treatment of advanced renal cell carcinoma (RCC).
In August 2021, The Japanese Ministry of Health, Labor, and Welfare approved the use of Opdivo (nivolumab) and CABOMETYX (cabozantinib) by Ono and Takeda for metastatic renal cell carcinoma treatment.

Frequently Asked Questions (FAQ)

The global kidney cancer drugs market is estimated at USD 7.09 billion in 2025.

The global kidney cancer drugs market was calculated at USD 6.9 billion in 2024 and is foreseen to expand at a CAGR of 5.5% and reach USD 13.47 billion by 2037.

Some of the leading companies are AbbVie, Baxter International Inc., Byer AG, GlaxoSmithKline Plc, Johnson & Johnson, and Merck & Co., Inc.

Angiogenesis inhibitors are estimated to capture 53.0% of the global market share by 2037 and are anticipated to lead the segment growth throughout the forecast period.

North America region holds 35.0% of the global market share by 2037 and is projected to offer lucrative prospects throughout the study period.

Kidney Cancer Drugs Market - Top Companies and Manufacturers

Companies Dominating the Kidney Cancer Drugs Landscape:

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the kidney cancer drugs market?

What is the outlook for the kidney cancer drugs market?

Who are the major key players dominating the kidney cancer drugs market?

Which pharmacological class type segment is expected to lead the kidney cancer drugs market by 2037?

Which region will provide more business opportunities for the growth of the kidney cancer drugs market in the future?